NasdaqGS:ARQTBiotechs
Is Strong Q1 Growth and Reaffirmed Guidance Altering The Investment Case For Arcutis Biotherapeutics (ARQT)?
Arcutis Biotherapeutics reported first-quarter 2026 revenue of US$105.4 million, up from US$65.85 million a year earlier, with net loss narrowing to US$11.3 million and full-year 2026 net product revenue guidance reaffirmed at US$480 million to US$495 million.
Alongside earlier Health Canada approval for Zoryve cream in mild to moderate atopic dermatitis, these results highlight how this lead product is increasingly shaping Arcutis’ revenue profile and operating performance.
We’ll now...